FDA approves Gilead’s next-generation HIV PrEP pill, Descovy

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy — a medication already used by those who have HIV — as its next-generation prevention drug.

The final approval follows an August vote in favor of Descovy as a pre-exposure prophylaxis medication, or PrEP, by an FDA advisory panel.